These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15383195)

  • 1. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Vanscoy GJ
    Curr Med Res Opin; 2004 Sep; 20(9):1459-60; author reply 1462-3. PubMed ID: 15383195
    [No Abstract]   [Full Text] [Related]  

  • 2. Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa.
    Sullivan SD
    Curr Med Res Opin; 2004 Sep; 20(9):1461; author reply 1462-3. PubMed ID: 15487107
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic interchange of darbepoetin alfa for epoetin alfa in a multiinstitution health care system.
    Adamson R; Lew I; Allen P; Misuro A; Malacrida P
    Am J Health Syst Pharm; 2005 Nov; 62(22):2416-9. PubMed ID: 16278336
    [No Abstract]   [Full Text] [Related]  

  • 6. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G; Hurley D; Whyte JL; Willey V; Wilson M; Kallich J
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
    Nakagawa T
    Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting.
    Kruep EJ; Basskin LE
    Am J Health Syst Pharm; 2005 Dec; 62(24):2597-603. PubMed ID: 16333057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: comparative analysis of drug utilization, costs, and hematologic response.
    Persson U; Borg S; Jansson S; Ekman T; Franksson L; Friesland S; Larsson AM
    Adv Ther; 2005; 22(3):208-24. PubMed ID: 16236682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New pharmacoeconomic option in uremic anemia management.
    Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
    Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
    [No Abstract]   [Full Text] [Related]  

  • 12. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.
    Brophy DF; Ripley EB; Kockler DR; Lee S; Proeschel LA
    Ann Pharmacother; 2005 Nov; 39(11):1808-11. PubMed ID: 16189281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P; Coiffier B; Zambrowski JJ
    Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
    Yang MC
    Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
    Longfield V; Gebhart B; Hayward L
    J Support Oncol; 2005; 3(6 Suppl 4):8-9. PubMed ID: 16355548
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting.
    Reichardt B
    J Clin Pharm Ther; 2006 Oct; 31(5):503-12. PubMed ID: 16958829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD; Cooper B
    Nephrology (Carlton); 2004 Aug; 9(4):223-8. PubMed ID: 15363054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.